BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00016965|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 24, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced pancreatic cancer.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Drug: ixabepilone||Phase 2|
- Determine the 6-month survival rate and time to treatment failure in patients with advanced pancreatic adenocarcinoma treated with BMS-247550.
- Determine the frequency and severity of toxic effects of this drug in these patients.
- Determine the complete and partial response in those patients with measurable disease treated with this drug.
- Determine the pharmacokinetic profile of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive BMS-247550 IV over 3 hours on day 1. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
Patients are followed every 6 months for 2 years and then annually until 3 years after registration.
PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer|
|Study Start Date :||July 2001|
|Actual Study Completion Date :||April 2006|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00016965
Show 95 Study Locations
|Study Chair:||Robert P. Whitehead, MD||University of Texas|